A San Diego manufacturer of highly-modified nucleic acids and its parent company have concluded that development of RNA- and oligonucleotide-based therapeutics—as well as the region’s biopharma cluster—will both grow strongly enough in the near future to justify the companies’ recent $50-million investment in relocation and expansion within the city.
BrightGene Bio-Medical Technology Co., said it has successfully manufactured the active pharmaceutical ingredients (APIs) of remdesivir (GS-5734), the Gilead Science antiviral candidate being tested in China human clinical trials as a treatment for 2019-nCoV novel coronavirus.
Taking a close look at the pros and cons of an increasingly popular biomanufacturing methodology.
Arrangement for Potelligent CHOKS1V covers research and commercial recombinant antibody production.
Centers aims to automate protocols for exome-capture and library-preparation workflows.
Collaboration aims to increase the availability of engineered T cell therapies by speeding up development of automation technologies
Sponsored Content Brought to you by As the pharmaceutical industry continues to look for new and innovative ways to treat disease, some companies are putting more focus on how to prevent them. Vaccine development, while...
GE Healthcare and Rockwell Automation are collaborating on a next-generation bioprocess automation platform to help biopharmaceutical companies create flexible and scalable facilities of the future, with a focus on streamlined production technologies and adaptable...
Please wait while you are redirected to the right page...